Skip to main content

We need more new antibiotics

By Helen Boucher, Special to CNN
June 13, 2013 -- Updated 2243 GMT (0643 HKT)
STORY HIGHLIGHTS
  • Obama administration is considering streamlining the approval process for antibiotics
  • Helen Boucher: For patients with life-threatening infections, access to new antibiotics is vital
  • She says by limiting their use to the sickest of the sick, we can minimize risks of new drugs
  • Boucher: We need to encourage more companies to do antibiotic research and development

Editor's note: Helen Boucher is director of the infectious diseases fellowship program and staff physician at Tufts Medical Center, and associate professor of medicine at Tufts University School of Medicine. She is a member of the Infectious Diseases Society of America's Antimicrobial Resistance Committee and serves in advisory roles related to antibiotic development for some pharmaceutical companies.

(CNN) -- For desperately ill patients with serious, life-threatening antibiotic-resistant infections, access to new antibiotics is a matter of life and death.

All across America, people are dying from bacterial infections that we used to be able to cure with antibiotics.

Just this March, the Centers for Disease Control and Prevention warned the public about a four-fold increase in one group of "nightmare bacteria," carbapenem-resistant Enterobacteriaceae, which kills up to 50% of the people infected, and is on the rise. The annual impact of antibiotic resistant infections on the U.S. health care system is estimated to be $21 billion to $34 billion in excess health care costs and more than 8 million additional hospital days. At the same time, we are not making new antibiotics fast enough to prevent these deaths.

Without new antibiotics, things we all take for granted, including surgery, chemotherapy, organ transplantation and premature infant care, will be in jeopardy. A streamlined but targeted approach that speeds regulatory approval of new antibiotics -- and limits their use to the sickest of the sick -- is an appropriate way to balance the safety risks of these new drugs with the lifesaving benefits they can offer patients who have no other treatment options.

Helen Boucher
Helen Boucher

As a practicing infectious disease physician, my colleagues and I are seeing firsthand the devastating effects that resistant infections have on patients.

Consider Addie Rerecich, who was a healthy, athletic 11-year-old in 2011 before she spent five months in an Arizona hospital battling several serious drug-resistant infections that her doctors did not have antibiotics powerful enough to treat. Addie ultimately needed a double lung transplant to save her life. The health care costs from her hospital stay alone totaled $6 million, and she will need medical attention and therapy for the rest of her life.

As resistant infections like those that nearly took Addie's life continue to increase, the antibiotic pipeline is nearly dry, with few drugs in development that will work against the most alarming pathogens our patients face.

A proposal from the Infectious Diseases Society of America aims to address a key part of the problem by reducing the obstacles to regulatory approval of new antibiotics for use in a distinct, narrow group of people: Patients with serious resistant infections that have no effective treatment options left.

How will this make a difference?

The current regulatory environment in the U.S. discourages drug companies from antibiotic research and development, and few firms are active in this area today. Antibiotics also aren't as profitable as other drugs, such as those for chronic conditions like heart disease or diabetes, which patients often take for years. A more direct path for regulatory approval can encourage more companies to get involved in antibiotic development again.

IDSA's approach -- the Limited Population Antibacterial Drug -- would speed patients' access to new, lifesaving antibiotics by allowing the Food and Drug Administration to approve them for narrow use based on smaller clinical trials than required for more widely used antibiotics. Under LPAD, drug companies will still have to show that a drug's benefits outweigh the risks in patients with serious infections. It's an idea modeled after the successful Orphan Drug Program, which encourages the development of drugs for rare diseases.

Promoting the appropriate use of these new antibiotics is critical, because we know antibiotic misuse and overuse are significant drivers of drug resistance.

Special labeling will ensure narrow marketing of these drugs. Educational efforts should be put in place to send a strong signal to health care providers, facilities and insurers that these drugs are only for patients who need them most. These drugs will also likely be priced higher, commensurate with their value as life-saving medicines, than traditionally approved antibiotics, another factor that will help limit their wider use.

Antibiotic stewardship programs, which encourage appropriate antibiotic use by providers and health facilities, will play a key role. These programs provide much needed support and guidance to clinicians and ensure that our precious resource of antibiotics will be used wisely.

Professional medical groups -- including the American Medical Association -- public health organizations, patient groups and pharmaceutical manufacturers have voiced their support for IDSA's proposal. FDA and several members of Congress are also interested in the concept and in moving it forward.

To be sure, developing new antibiotics and speeding their approval process to treat seriously ill patients is just one way to grapple with this complex public health crisis.

IDSA also promotes enhanced public health efforts, including better data collection and surveillance of drug resistance and the use of antibiotics, improved infection prevention, antimicrobial stewardship, and stronger efforts to encourage the appropriate use of antibiotics in humans and on the farm. Increased research funding to explore how antibiotic resistance develops and spreads is just as vital, along with additional economic incentives and regulatory clarity to boost antibiotic development.

Patients like Addie need our help. We must take action now.

Follow @CNNOpinion on Twitter.

Join us at Facebook/CNNOpinion.

The opinions expressed in this commentary are solely those of Helen Boucher.

ADVERTISEMENT
Part of complete coverage on
April 23, 2014 -- Updated 1641 GMT (0041 HKT)
Robert Hickey says most new housing development is high-end, catering to high-earners.
April 23, 2014 -- Updated 1317 GMT (2117 HKT)
Alexander Motyl says as Russian President Putin snarled at Ukraine, his foreign minister was signing a conciliatory accord with the West. Whatever the game, the accord is a major stand down by Russia
April 23, 2014 -- Updated 1229 GMT (2029 HKT)
Les Abend says at every turn, the stowaway teen defied the odds of discovery and survival. What pilot would have thought to look for a person in the wheel well?
April 22, 2014 -- Updated 2247 GMT (0647 HKT)
Q & A with artist Rachel Sussman on her new book of photographs, "The Oldest Living Things in the World."
April 22, 2014 -- Updated 1958 GMT (0358 HKT)
Martin Blaser says the overuse of antibiotics threatens to deplete our bodies of "good" microbes, leaving us vulnerable to an unstoppable plague--an "antibiotic winter"
April 22, 2014 -- Updated 1737 GMT (0137 HKT)
John Sutter asks: Is it possible to eat meat in modern-day America and consider yourself an environmentalist without being a hypocrite?
April 22, 2014 -- Updated 1538 GMT (2338 HKT)
Sally Kohn notes that Meb Keflezighi rightly was called an American after he won the Boston Marathon, but his status in the U.S. once was questioned
April 22, 2014 -- Updated 1256 GMT (2056 HKT)
Denis Hayes and Scott Denman say on this Earth Day, the dawn of the Solar Age is already upon us and the Atomic Age of nuclear power is in decline
April 21, 2014 -- Updated 2036 GMT (0436 HKT)
Retired Coast Guard officer James Loy says a ship captain bears huge responsibility.
April 21, 2014 -- Updated 1708 GMT (0108 HKT)
Peter Bergen says the latest strikes are part of an aggressive U.S. effort to target militants, including a bomb maker
April 21, 2014 -- Updated 1345 GMT (2145 HKT)
Cynthia Lummis and Peter Welch say 16 agencies carry out national intelligence, and their budgets are top secret. We need to know how they are spending our money.
April 21, 2014 -- Updated 1235 GMT (2035 HKT)
Julian Zelizer says President Obama knows more than anyone that he has much at stake in the midterm elections.
April 22, 2014 -- Updated 1255 GMT (2055 HKT)
Eric Sanderson says if you really want to strike a blow for the environment--and your health--this Earth Day, work to get cars out of cities and create transportation alternatives
April 21, 2014 -- Updated 1408 GMT (2208 HKT)
Bruce Barcott looks at the dramatic differences in marijuana laws in Colorado and Louisiana
April 18, 2014 -- Updated 2047 GMT (0447 HKT)
Jim Bell says NASA's latest discovery supports the notion that habitable worlds are probably common in the galaxy.
April 18, 2014 -- Updated 1817 GMT (0217 HKT)
Jay Parini says even the Gospels skip the actual Resurrection and are sketchy on the appearances that followed.
April 18, 2014 -- Updated 1752 GMT (0152 HKT)
Graham Allison says if an unchecked and emboldened Russia foments conflict in a nation like Latvia, a NATO member, the West would have to defend it.
April 18, 2014 -- Updated 1311 GMT (2111 HKT)
John Sutter: Bad news, guys -- the pangolin we adopted is missing.
April 21, 2014 -- Updated 1825 GMT (0225 HKT)
Ben Wildavsky says we need a better way to determine whether colleges are turning out graduates with superior education and abilities.
April 18, 2014 -- Updated 1026 GMT (1826 HKT)
Charles Maclin, program manager working on the search and recovery of Malaysia Flight 370, explains how it works.
April 18, 2014 -- Updated 1250 GMT (2050 HKT)
Jill Koyama says Michael Bloomberg is right to tackle gun violence, but we need to go beyond piecemeal state legislation.
April 17, 2014 -- Updated 1845 GMT (0245 HKT)
Michael Bloomberg and Shannon Watts say Americans are ready for sensible gun laws, but politicians are cowed by the NRA. Everytown for Gun Safety will prove the NRA is not that powerful.
ADVERTISEMENT